InMed Pharmaceuticals Reports Q1 GAAP EPS of -$0.36 and Declining Cash Reserves
InMed Pharmaceuticals (INM) has reported a GAAP earnings per share (EPS) of -$0.36 for the first quarter. The company's liquidity position has weakened significantly, with cash and cash equivalents dropping to $1.0 million as of September 30, 2026, down from $2.2 million at the end of June 2026. Management is currently focused on managing expenses while attempting to finalize a proposed merger with Mentari and exploring strategic options for its legacy pharmaceutical assets. Due to current burn rates, InMed expects its remaining cash to sustain operations only through mid-November 2026, contingent upon the timing of the merger completion.